Pulmonx Free Cash Flow vs Free Cash Flow Yield Analysis
LUNG Stock | USD 6.45 0.15 2.38% |
Pulmonx Corp financial indicator trend analysis is much more than just breaking down Pulmonx Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pulmonx Corp is a good investment. Please check the relationship between Pulmonx Corp Free Cash Flow and its Free Cash Flow Yield accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pulmonx Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.
Free Cash Flow vs Free Cash Flow Yield
Free Cash Flow vs Free Cash Flow Yield Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pulmonx Corp Free Cash Flow account and Free Cash Flow Yield. At this time, the significance of the direction appears to have strong relationship.
The correlation between Pulmonx Corp's Free Cash Flow and Free Cash Flow Yield is 0.78. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Pulmonx Corp, assuming nothing else is changed. The correlation between historical values of Pulmonx Corp's Free Cash Flow and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Pulmonx Corp are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Free Cash Flow i.e., Pulmonx Corp's Free Cash Flow and Free Cash Flow Yield go up and down completely randomly.
Correlation Coefficient | 0.78 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Most indicators from Pulmonx Corp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pulmonx Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pulmonx Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.The Pulmonx Corp's current Selling General Administrative is estimated to increase to about 94.3 M, while Tax Provision is projected to decrease to roughly 339.7 K.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 3.2M | 4.0M | 1.9M | 1.8M | Interest Income | 400K | 1.5M | 4.8M | 5.0M |
Pulmonx Corp fundamental ratios Correlations
Click cells to compare fundamentals
Pulmonx Corp Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pulmonx Corp fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 53.5M | 263.7M | 235.2M | 193.7M | 177.8M | 94.3M | |
Total Current Liabilities | 14.2M | 12.5M | 17.6M | 18.5M | 23.2M | 24.3M | |
Total Stockholder Equity | (187.4M) | 226.1M | 193.2M | 154.0M | 118.3M | 124.2M | |
Net Tangible Assets | (190.2M) | 223.4M | 190.6M | 151.7M | 174.4M | 183.1M | |
Retained Earnings | (210.5M) | (242.7M) | (291.4M) | (350.3M) | (411.2M) | (390.6M) | |
Accounts Payable | 2.7M | 1.5M | 1.6M | 1.8M | 1.5M | 1.2M | |
Cash | 14.8M | 231.6M | 148.5M | 101.7M | 83.5M | 58.5M | |
Long Term Debt | 15.0M | 17.4M | 17.3M | 17.2M | 35.1M | 36.8M | |
Inventory | 5.6M | 10.7M | 16.3M | 14.6M | 16.7M | 17.6M | |
Total Liab | 240.9M | 37.6M | 41.9M | 39.7M | 59.5M | 61.4M | |
Total Current Assets | 41.1M | 250.0M | 208.0M | 169.0M | 150.4M | 83.2M | |
Short Term Debt | 446K | 4.5M | 2.3M | 6.5M | 8.3M | 8.7M | |
Common Stock | 19K | 36K | 37K | 38K | 39K | 25.0K | |
Property Plant Equipment | 7.5M | 10.5M | 12.9M | 5.3M | 6.1M | 4.1M | |
Net Receivables | 5.9M | 4.2M | 6.6M | 8.7M | 12.1M | 6.5M | |
Other Assets | 2.1M | 536K | 731K | 5.8M | 1.0 | 0.95 | |
Other Current Assets | 766K | 3.1M | 4.8M | 4.0M | 3.6M | 2.0M | |
Intangible Assets | 524K | 400K | 277K | 154K | 31K | 29.5K | |
Short Long Term Debt Total | 21.8M | 27.2M | 26.5M | 24.4M | 41.4M | 32.1M | |
Other Current Liab | 10.9M | 6.4M | 13.4M | 10.0M | 13.2M | 11.0M | |
Other Liab | 43K | 62K | 37K | 94K | 84.6K | 58.1K | |
Property Plant And Equipment Net | 7.5M | 10.5M | 12.9M | 10.5M | 7.4M | 9.0M | |
Current Deferred Revenue | 173K | 71K | 163K | 120K | 104K | 102.7K | |
Net Debt | 7.0M | (204.3M) | (122.0M) | (77.3M) | (42.1M) | (44.2M) | |
Non Current Assets Total | 12.5M | 13.7M | 27.2M | 24.7M | 27.4M | 20.0M | |
Non Currrent Assets Other | 2.1M | 536K | 252K | 5.4M | 3.2M | 2.2M | |
Cash And Short Term Investments | 28.3M | 231.6M | 180.0M | 141.1M | 117.1M | 128.8M | |
Common Stock Total Equity | 19K | 36K | 37K | 38K | 43.7K | 32.3K | |
Common Stock Shares Outstanding | 35.4M | 35.7M | 36.1M | 37.1M | 38.0M | 37.2M | |
Liabilities And Stockholders Equity | 53.5M | 263.7M | 235.2M | 193.7M | 177.8M | 172.1M | |
Non Current Liabilities Total | 226.8M | 25.0M | 24.4M | 21.2M | 36.3M | 67.7M | |
Capital Lease Obligations | 6.8M | 9.9M | 9.0M | 7.1M | 4.2M | 6.8M | |
Other Stockholder Equity | (183.6M) | 467.1M | 482.9M | 502.7M | 526.8M | 333.1M | |
Net Invested Capital | (172.4M) | 243.5M | 210.7M | 171.3M | 155.6M | 87.1M | |
Property Plant And Equipment Gross | 7.5M | 10.5M | 4.8M | 4.7M | 12.3M | 7.3M | |
Accumulated Other Comprehensive Income | 1.4M | 1.7M | 1.7M | 1.6M | 2.6M | 1.9M | |
Capital Stock | 19K | 36K | 37K | 38K | 39K | 34.1K | |
Net Working Capital | 26.9M | 237.5M | 190.5M | 150.5M | 127.3M | 134.9M |
Currently Active Assets on Macroaxis
When determining whether Pulmonx Corp is a strong investment it is important to analyze Pulmonx Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmonx Corp's future performance. For an informed investment choice regarding Pulmonx Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pulmonx Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmonx Corp. If investors know Pulmonx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmonx Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share 2.043 | Quarterly Revenue Growth 0.154 | Return On Assets (0.20) | Return On Equity (0.52) |
The market value of Pulmonx Corp is measured differently than its book value, which is the value of Pulmonx that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmonx Corp's value that differs from its market value or its book value, called intrinsic value, which is Pulmonx Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmonx Corp's market value can be influenced by many factors that don't directly affect Pulmonx Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmonx Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmonx Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmonx Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.